Complementary Approaches to Existing Target Based Drug Discovery for Identifying Novel Drug Targets
Overview
Affiliations
In the past decade, it was observed that the relationship between the emerging New Molecular Entities and the quantum of R&D investment has not been favorable. There might be numerous reasons but few studies stress the introduction of target based drug discovery approach as one of the factors. Although a number of drugs have been developed with an emphasis on a single protein target, yet identification of valid target is complex. The approach focuses on an in vitro single target, which overlooks the complexity of cell and makes process of validation drug targets uncertain. Thus, it is imperative to search for alternatives rather than looking at success stories of target-based drug discovery. It would be beneficial if the drugs were developed to target multiple components. New approaches like reverse engineering and translational research need to take into account both system and target-based approach. This review evaluates the strengths and limitations of known drug discovery approaches and proposes alternative approaches for increasing efficiency against treatment.
Single molecule tracking based drug screening.
Watanabe D, Hiroshima M, Yasui M, Ueda M Nat Commun. 2024; 15(1):8975.
PMID: 39420015 PMC: 11486946. DOI: 10.1038/s41467-024-53432-w.
Otero-Carrasco B, Ugarte Carro E, Prieto-Santamaria L, Diaz Uzquiano M, Caraca-Valente Hernandez J, Rodriguez-Gonzalez A BMC Genomics. 2024; 25(1):43.
PMID: 38191292 PMC: 10775474. DOI: 10.1186/s12864-023-09913-1.
infection: novel emerging therapeutic targets.
Muller J, Hemphill A Expert Opin Ther Targets. 2023; 27(4-5):293-304.
PMID: 37212443 PMC: 10330558. DOI: 10.1080/14728222.2023.2217353.
Efforts Made to Eliminate Drug-Resistant Malaria and Its Challenges.
Amelo W, Makonnen E Biomed Res Int. 2021; 2021:5539544.
PMID: 34497848 PMC: 8421183. DOI: 10.1155/2021/5539544.
Chronic Inflammatory Diseases, Anti-Inflammatory Agents and Their Delivery Nanosystems.
Placha D, Jampilek J Pharmaceutics. 2021; 13(1).
PMID: 33419176 PMC: 7825503. DOI: 10.3390/pharmaceutics13010064.